Ping Xiao

Ping Xiao

Auto-generated profile, based on publicly available information

Ping Xiao

Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
XXXiangcheng Xiao
Xiangcheng Xiao
QYQiongjing Yuan
Qiongjing Yuan
YCYusa Chen
Yusa Chen
ZHZhihua Huang
Zhihua Huang
XFXi Fang
Xi Fang
PXPing Xiao
Ping Xiao

26 March 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
TWTing Wu
Ting Wu
CSChanjuan Shen
Chanjuan Shen
YZYong Zhong
Yong Zhong
JOJoshua D. Ooi
Joshua D. Ooi
YZYa-Ou Zhou
Ya-Ou Zhou
PXPing Xiao
Ping Xiao
In antineutrophil cytoplasmic autoantibody (ANCA)‑associated vasculitides (AAV), the two major target antigens of ANCA are proteinase 3 (PR3) and myeloperoxidase (MPO). Evidence is accumulating that there are distinct differences between patients with PR3‑AAV and those with MPO‑AAV. In the present study, the clinicopathological features and prognosis of patients with PR3‑AAV and MPO‑AAV from a single center in China were retrospectively analyzed. A total of 212 Chinese patients with AAV were recruited in the present study; 189/212 (89.15%) patients were classified as having MPO‑AAV and 23/212 (10.85%) patients as having PR3‑AAV. Compared with those in the PR3‑AAV group, patients in the MPO‑AAV group were older and less frequently had ear, nose and throat or ophthalmic involvement. MPO‑AAV patients had higher levels of serum creatinine and proteinuria at baseline. No significant difference was observed with regard to the pathological changes of the glomeruli and tubulointerstitium between the two groups. The probability of developing end‑stage renal disease was significantly higher in patients with MPO‑AAV compared with that in patients with PR3‑AAV. There was no significant difference in the one‑year patient survival rate between the two groups. However, differences in certain clinical characteristics and outcomes were observed between MPO‑AAV and PR3‑AAV patients. A large national investigation of AAV is required to confirm the concept that PR3‑AAV and MPO‑AAV are distinct disease entities.

22 September 2021 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
TMTing Meng
Ting Meng
CSChanjuan Shen
Chanjuan Shen
RTRong Tang
Rong Tang
WLWei Lin
Wei Lin
JOJoshua D. Ooi
Joshua D. Ooi
XXXiangcheng Xiao
Xiangcheng Xiao